NDAORALFOR SUSPENSION
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
3/8 — Basic
OMNICEF (cefdinir) by AbbVie is clinical pharmacology pharmacokinetics and drug metabolism absorption oral bioavailability maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule administration. First approved in 1997.
Drug data last refreshed 14h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics and Drug Metabolism Absorption Oral Bioavailability Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from…
Worked on OMNICEF at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.